The 2026 guideline introduces AHA/ACC Acute Pulmonary Embolism Clinical Categories to improve severity classification and evidence-based management of acute pulmonary embolism.
The Clinical Valve Coordinator is essential for improving access to care and patient outcomes in multidisciplinary teams managing valvular heart disease.
Luteolin improved left ventricular ejection fraction (LVEF) and reduced inflammatory factors in atherosclerotic mice, indicating potential as a cardiovascular protective agent.
Anxiety and depression significantly reduced treatment effectiveness and increased major cardiovascular adverse events in ACS patients after PCI, compared to those without these conditions.
Finerenone reduced heart failure events and cardiovascular deaths in patients with heart failure and EF ≥40%, showing promise for HFpEF and HFmrEF treatments.
In patients with HFrEF receiving guideline-directed medical therapy, 75% with ≥moderate MR and TR experienced regression to no/mild levels over 7.1 months.
Early cardiac rehabilitation with levosimendan infusion and M-TEER improved clinical stability and functional outcomes in a high-risk elderly STEMI patient.
Transfer patients with anticoagulation-associated intracerebral hemorrhage had longer times to anticoagulant reversal, but lower odds of in-hospital death (OR 0.78).
The Random Forest model achieved 84.6% accuracy in predicting physical activity adherence, identifying key predictors like step count variance and heart rate recovery.
Dapagliflozin combined with sacubitril valsartan sodium improved cardiac function (higher LVEF, lower LVEDVI and LVESVI) and reduced blood glucose fluctuations in CHF and DM patients.